In 2020, van der Geer, et. al., conducted study about Trismus, characterized by restricted mouth opening, is a common issue in head and neck cancer patients. This study aimed to assess and compare the effectiveness of two stretching devices, the TheraBite® Jaw Motion Rehabilitation System™ and the Dynasplint Trismus System®, in improving maximal mouth opening (MMO) in this patient population.

A randomized controlled trial was conducted, assigning patients to either the TheraBite® or Dynasplint group. Participants engaged in a three-month stretching exercise protocol. Maximal mouth opening was measured during three study visits, and patients completed questionnaires on mandibular function and quality of life.

Among the 27 participants, five did not initiate the exercise protocol, eight discontinued exercises, and two were lost to follow-up. No significant differences were observed in the change in mouth opening between the two devices. The TheraBite® group showed an increase in MMO of 3.0 mm (IQR – 2.0; 4.0), while the Dynasplint group exhibited a 1.5 mm increase (IQR 1.0; 3.0). Challenges faced by patients included the intensive exercise protocol, pain during exercises, fitting issues with the stretching device, and overall deterioration of their medical condition.

This study found no significant differences in the effects of the TheraBite® and Dynasplint devices on trismus in head and neck cancer patients. Factors influencing exercise progression, such as patient-reported pain and device fitting problems, should be considered when prescribing stretching regimens for this population. These findings contribute to our understanding of trismus management and highlight the importance of tailoring interventions to individual patient needs.

Reference: van der Geer, S. J., Reintsema, H., Kamstra, J. I., Roodenburg, J. L., & Dijkstra, P. U. (2020). The use of stretching devices for treatment of trismus in head and neck cancer patients: a randomized controlled trial. Supportive Care in Cancer, 28, 9-11.